Peter A McSweeney

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    P A McSweeney
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA
    Blood 97:3390-400. 2001
  2. pmc High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes
    Peter A McSweeney
    University of Colorado Health Sciences Center, Denver 80262, USA
    Blood 100:1602-10. 2002
  3. pmc High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:1388-96. 2007
  4. ncbi request reprint Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing
    Michael B Maris
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 12:454-65. 2006
  5. ncbi request reprint Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation
    Frederic Baron
    Fred Hutchinson Cancer Research Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98109 1024, USA
    J Clin Oncol 24:4150-7. 2006
  6. ncbi request reprint Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation
    Christian Junghanss
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 123:662-70. 2003
  7. ncbi request reprint Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant
    Lyle C Feinstein
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 9:266-72. 2003
  8. pmc Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 9:583-91. 2003
  9. pmc Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 13:423-32. 2007
  10. pmc Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation
    Rainer Storb
    University of Washington, USA
    J Clin Oncol 31:1530-8. 2013

Detail Information

Publications30

  1. ncbi request reprint Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    P A McSweeney
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA
    Blood 97:3390-400. 2001
    ..Future protocol modifications should reduce rejection and GVHD, thereby facilitating studies of allogeneic immunotherapy for a variety of malignancies. (Blood. 2001;97:3390-3400)..
  2. pmc High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes
    Peter A McSweeney
    University of Colorado Health Sciences Center, Denver 80262, USA
    Blood 100:1602-10. 2002
    ..Responses in skin and mHAQ-DI scores exceed those reported with other therapies, suggesting that HDIT is a promising new therapy for SSc that should be evaluated in prospective randomized studies...
  3. pmc High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:1388-96. 2007
    ..Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies. HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial...
  4. ncbi request reprint Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing
    Michael B Maris
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 12:454-65. 2006
    ..Nonmyeloablative conditioning with postgrafting cyclosporine and MMF given 3 times daily allowed 95% durable engraftment of unrelated donor G-PBMC grafts...
  5. ncbi request reprint Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation
    Frederic Baron
    Fred Hutchinson Cancer Research Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98109 1024, USA
    J Clin Oncol 24:4150-7. 2006
    ..Although most studies showed relatively low nonrelapse mortality (NRM) rates and encouraging short-term results, it has yet to be defined which patients would benefit most from these approaches...
  6. ncbi request reprint Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation
    Christian Junghanss
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 123:662-70. 2003
    ....
  7. ncbi request reprint Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant
    Lyle C Feinstein
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 9:266-72. 2003
    ..4; P =.04). Although the length of follow-up is still short, it appears that encouraging outcomes can be achieved with nonmyeloablative conditioning in patients expected to have poor outcomes with conventional allografting...
  8. pmc Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 9:583-91. 2003
    ..The differences between equine and rabbit ATG are not yet clearly defined, and they should not be considered interchangeable in this regimen without further study...
  9. pmc Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 13:423-32. 2007
    ....
  10. pmc Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation
    Rainer Storb
    University of Washington, USA
    J Clin Oncol 31:1530-8. 2013
    ..The regimen allows the purest assessment of graft-versus-tumor (GVT) effects apart from conditioning and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities...
  11. pmc Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Clin Oncol 26:4912-20. 2008
    ..Here, we have extended the follow-up to a median of 5 years and have included data on an additional 18 patients...
  12. pmc Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Arthritis Rheum 54:1982-6. 2006
    ..To evaluate the safety and efficacy of allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning in patients with severe systemic sclerosis (SSc)...
  13. pmc Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies
    Mohamed L Sorror
    Transplantation Biology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    JAMA 306:1874-83. 2011
    ..A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced hematologic malignancies who are older or have comorbid conditions...
  14. pmc Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
    Marcello Rotta
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:3383-91. 2009
    ..03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues...
  15. pmc High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:2364-72. 2003
    ..This was a heterogeneous high-risk group, and a phase 3 study is planned to fully assess efficacy...
  16. ncbi request reprint Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study
    Christian Junghanss
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 8:512-20. 2002
    ..This risk is an important consideration for the future development of preventive strategies...
  17. pmc Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Christoph Kahl
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:2744-8. 2007
    ..The latter might benefit from cytoreductive treatment before HCT...
  18. ncbi request reprint Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission
    Lyle C Feinstein
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Br J Haematol 120:281-8. 2003
    ..While follow-up is short, this analysis demonstrates that the procedure is sufficiently safe to be studied in a wider group of patients...
  19. ncbi request reprint Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
    Int J Hematol 76:184-9. 2002
    ..Related and unrelated nonmyeloablative HSCT is feasible and potentially curative in patients with advanced hematological malignancies who have no other treatment options...
  20. ncbi request reprint HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia
    Frederic Baron
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:272-9. 2005
    ..Further efforts are directed at reducing the risk of graft rejection by exclusive use of G-PBMC and increasing the degree of pretransplantation immunosuppression...
  21. doi request reprint Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation
    Mohamed Sorror
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Cancer 112:1992-2001. 2008
    ..Herein, a recently developed HCT-specific comorbidity index (HCT-CI) was compared with a widely acceptable measure of health status, the Karnofsky performance status (KPS)...
  22. pmc Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)
    Jan Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
    Clin Immunol 113:285-98. 2004
    ..In conclusion, peripheral expansion of CD8 but not CD4 T cells is highly efficient. Prolonged CD4 lymphopenia is associated with relatively few infections, possibly due to antibodies produced by persisting pretransplant plasma cells...
  23. ncbi request reprint Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center, University of Washington, School of Medicine, Seattle, Washington 98109 1024, USA
    J Clin Immunol 22:70-4. 2002
    ..Enhancing graft-versus-tumor effects by virtue of postgrafting vaccination of recipients against tumor-specific antigens may help to use this transplant approach more effectively in the treatment of solid tumors...
  24. pmc Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Mail Stop D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 108:1485-91. 2006
    ..Thus, low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions...
  25. ncbi request reprint Treatment options for newly diagnosed patients with chronic myeloid leukemia
    Lori J Maness
    University of Colorado Health Sciences Center, 4200 East Ninth Avenue B 190, Denver, CO 80262, USA
    Curr Hematol Rep 3:54-61. 2004
    ..Sensitive and specific monitoring techniques developed for CML may help further refine treatment with regard to using these and other emerging therapies...
  26. ncbi request reprint Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer
    Yago Nieto
    University of Colorado Bone Marrow Transplant Program and Department of Pathology, University of Colorado, Denver, CO 80262, USA
    J Clin Oncol 20:707-18. 2002
    ..To study prognostic factors after high-dose chemotherapy (HDC) for patients with stage IV oligometastatic breast cancer...
  27. ncbi request reprint Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant
    Yago Nieto
    Bone Marrow Transplant Program and Departments of Pathology and Biostatistics, University of Colorado, Denver, Colorado 80262, USA
    Clin Cancer Res 10:5076-86. 2004
    ....
  28. ncbi request reprint Reduced-intensity allogeneic transplantation for lymphoma
    Karen E Kogel
    University of Colorado Health Sciences Center, Denver 80262, USA
    Curr Opin Oncol 14:475-83. 2002
    ..Controlled trials involving patients with earlier-stage disease appear warranted to define better the role of reduced-intensity allogeneic transplants in treating lymphomas...
  29. ncbi request reprint Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer
    Yago Nieto
    Bone Marrow Transplant Program and Department of Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Cancer Res 10:7136-43. 2004
    ....
  30. ncbi request reprint Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study
    Christian Junghanss
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Blood 99:1978-85. 2002
    ..Therefore, nonmyeloablative HSCT patients should receive CMV surveillance beyond day 100 and pre-emptive ganciclovir treatment similar to that of myeloablative HSCT patients...